Covid-19 roundup: Mesoblast takes an­oth­er hit as FDA de­mands ad­di­tion­al tri­al ahead of any EUA re­view

Shares of Mesoblast $MESO tum­bled 12% on Tues­day af­ter the small Aus­tralian biotech re­port­ed that the FDA is de­mand­ing an­oth­er tri­al be­fore the agency will con­sid­er an emer­gency au­tho­riza­tion for their ex­per­i­men­tal drug remestem­cel-L for Covid pa­tients suf­fer­ing from acute res­pi­ra­to­ry dis­tress syn­drome.

Read the source article at endpts.com
2021-09-01 11:11:33